Pharmacognosy intro
Lepidium meyenii Walp. (syn. L. peruvianum Chacon), family Brassicaceae, is a cruciferous root vegetable cultivated at 4,000-4,500m altitude on Peru's Junin Plateau for over 2,000 years. The swollen hypocotyl (fused root-axis structure) is used. Unique bioactives include macamides (N-benzylamide fatty acid derivatives found exclusively in Maca) and macaenes (polyunsaturated fatty acids). Additional compounds include glucosinolates (glucotropaeolin, glucolimnanthin), macaridine, unique imidazole-type alkaloids, beta-sitosterol, and minerals including iron, copper, zinc, and iodine. Quality products standardize to >0.5% macamides. Yellow, red, and black ecotypes have different phytochemical ratios and partially different clinical applications: black Maca shows strongest effects on spermatogenesis and memory, red on prostate and bone density. Maca does not contain phytoestrogens, phytoandrogens, or plant hormones, and does not directly alter testosterone, estrogen, or LH/FSH levels in human studies. This is a critical pharmacological distinction. The mechanism operates through hypothalamic-pituitary axis modulation without direct hormonal activity. Macamides interact with the endocannabinoid system through FAAH (fatty acid amide hydrolase) inhibition, increasing endogenous anandamide levels. Hahn et al. (2020, FASEB J) identified macamides as potent Nrf2 activators (EC50 7.3-16.5 microM), establishing a molecular basis for neuroprotective and antioxidant effects. BDNF upregulation occurs via PI3K/Akt signaling. Serotonin synthesis enhancement through gut-brain axis tryptophan metabolism modulation contributes to antidepressant-like effects. Chen et al. (2021, Phytother Res) conducted a systematic review and meta-analysis of 3 RCTs (n=123 total) showing Maca significantly improved IIEF-5 scores in mild erectile dysfunction (p<0.001). Gonzales et al. (2002, Andrologia) first demonstrated that 1.5-3g/day for 12 weeks improved sexual desire without changing serum testosterone, estradiol, or LH levels (n=56 healthy men). Dording et al. (2008, CNS Neurosci Ther) showed 3g/day improved SSRI-induced sexual dysfunction in women (ASEX scores, p=0.028, n=20). Trials are small (n=9-123) and most sexual function evidence originates from a single research group. Product variability across ecotype and processing method (raw versus gelatinized) significantly affects outcomes. The non-hormonal mechanism remains incompletely understood.